���构特征与受体作用机制 — Worked Examples

By Editorial Desk · published 2025-11-16 · last reviewed 2025-12-03 · Info

This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-12-03 and is reviewed periodically as new material appears.

结构特征与受体作用机制

皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

Background and Molecular Design

Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.

Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.

The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.

Semaglutide at a glance

Handling, Storage, and Characterization

Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.

Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.

Related pages on this site

• Lightweight guide
• Adaptive reference
• Portable primer
• Professional comparison
• Durable dataset
• Scalable notes
• Balanced briefing
• Proven index

Semaglutide Structure and Receptor Mechanism

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.

Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.

Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.

Supporting material

=== Oxazolidines === Oxazolidines are a five-membered ring compounds consisting of three carbons, a nitrogen, and an oxygen. The oxygen and NH are the 1 and 3 positions, respectively. In oxazolidine derivatives, there is always a carbon between the oxygen and the nitrogen.

Deinococcus radiodurans Acute radiation syndrome, effects of exposure to high levels of ionizing radiation Food labeling regulations Food and cooking hygiene Irradiated mail Chemical sterilization Radappertization Radicidation Radura

My book The Sun, the Genome, and the Internet (1999) describes a vision of green technology enriching villages all over the world and halting the migration from villages to megacities. The three components of the vision are all essential: the sun to provide energy where it is needed, the genome to provide plants that can convert sunlight into chemical fuels cheaply and efficiently, the Internet to end the intellectual and economic isolation of rural populations. With all three components in place, every village in Africa could enjoy its fair share of the blessings of civilization. Dyson coined the term "green technologies", based on biology instead of physics or chemistry, to describe new species of microorganisms and plants designed to meet human needs. He argued that such technologies would be based on solar power rather than the fossil fuels whose use he saw as part of what he calls "gray technologies" of industry. He believed that genetically engineered crops, which he described as green, can help end rural poverty, with a movement based in ethics to end the inequitable distribution of wealth on the planet.

Sources: en.wikipedia.org

Supporting material

=== Diabulimia === Diabulimia is caused by a range of factors relating to body image, the regular use of insulin, and emotional well-being. The long-term management of type 1 diabetes often involves dietary restrictions for control of blood sugar level, which can raise a negative attention to diet. There is often a focus on the fact that insulin can cause weight gain, and that not using insulin can cause weight loss. For example, a person with type 1 diabetes may have experienced weight loss before the diagnosis, followed by weight gain when beginning treatment with insulin. This may lead to increased body dissatisfaction and preoccupation with weight loss. This increases the risk of eating disorders such as anorexia nervosa and bulimia nervosa. The vast majority of people with diabulimia are aware of the negative side effects that hyperglycemia can cause. Skipping insulin can lead to weight loss without side effects at first, but the risk of side effects gets progressively worse - by this time, it is more difficult to change behavior. Weight gain can cause individuals to fear insulin as it is often seen as the root of their low self-esteem. Low self-esteem can lead to depression or anxiety about body image that contributes to difficulty with diabetes management. Often, individuals often think diabulimia is less common than it is and do not know how difficult it is to overcome. Unlike vomiting or starving, there is sometimes no clear action or willpower involved. Often, individuals will refuse to believe in the diagnosis or the long-term effects.

=== H2 Relaxin === In the human ovary, H2 relaxin is produced by the corpus luteum and by Granulosa cells from large antral follicles. Research has shown that the relaxin gene is expressed once the Granulosa cells have reached a certain luteinised status, by which Granulosa cells differentiate into Luteal cells. Therefore, it can act as a good biomarker in relation to Granulosa cell differentiation status. Relaxin is produced to support early pregnancy until the placenta can take over. Relaxin plays a key role in implantation and placenta formation. The relaxin receptor RXFP1 is found on myometrial cells. In rats, it has been linked playing a role in the spacing between embryos in the uterus. RXFP1 is also located on endometrial stromal cells where it can induce cyclic adenosine monophosphate (cAMP). cAMP is a molecule which is necessary for the functional changes in the endometrium to form the decidual lining, where the blastocyst can implant. This results in neo-angiogenesis and endometrial thickening, both linked to early pregnancy development.

In the EU member states legislation was introduced in 1998 which had a major effect on UK Pharmacy operations. It effectively prohibited the use of tablet counters for counting and dispensing bulk packaged tablets. Both usage and sales of the machines in the UK declined rapidly as a result of the introduction of blister packaging for medicines.

== Synthesis == The synthesis of metal carbonyls is a widely studied subject of organometallic research. Since the work of Mond and then Hieber, many procedures have been developed for the preparation of mononuclear metal carbonyls as well as homo- and heterometallic carbonyl clusters.

Sources: en.wikipedia.org

Frequently asked questions